The World Bank lowered its China growth forecast for the year from 4.3 percent predicted in June to 2.7 percent due to the impact of the pandemic and property sector weaknesses on its economy.
The institution also slashed its forecast for next year from 8.1 percent down to 4.3 percent.
Many analysts believe that China's GDP growth target of around 5.5 percent for the year is now unattainable.
According to the World Bank, outbreaks and growth slowdowns in China have been followed by uneven recoveries.
Disruption to businesses has continued in China as cases surge and some restrictions remain in place.
Health officials have acknowledged that since bulk testing criteria were removed, official data no longer accurately reflect domestic infections.
The IMF forewarned last week that it will likely also reduce its predictions for China, blaming a sustained rise in cases.
The fund revised its growth forecast for China in October, lowering it to 3.2 percent this year, the lowest level in decades from the 4.4 percent it expected the previous year.
According to IMF chief Kristalina Georgieva, they are very likely to downgrade the growth projections for China, both for 2022 and 2023,
As China moves forward with the reopening, experts worry that it is ill-prepared to handle the next wave of diseases since millions of susceptible elderly people have not yet had all of the recommended vaccinations.


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Thailand Inflation Remains Negative for 10th Straight Month in January 



